SPIRIT TECH COLLECTIVE

Compass Pathways reported Q2 2026 financial results with key milestones toward potential FDA approval of COMP360 psilocybin-assisted therapy. The FDA granted rolling NDA submission with all modules targeted for Q4 2026 completion. Management cited approximately 90% prescriber intent among interventional psychiatrists. Cash position of $433.3 million extends runway through launch and into 2028. Commercial launch targeted for H1 2027, subject to FDA approval and DEA rescheduling. CEO Kabir Nath stated: 'The first half of 2026 marked a defining period for Compass as we continued to build momentum across clinical, regulatory and commercial fronts.'

Compass Pathways elected Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders, announced May 28, 2026. Tregoning most recently served as Chief Corporate Affairs Officer and Head of Commercial Strategy at Cerevel Therapeutics, guiding the company through its acquisition by AbbVie in 2024. Previously she was EVP of External Affairs at Sanofi and held health policy roles in the U.S. Congress. She holds a B.A. from Stanford and an M.A. from Harvard Kennedy School. The biopharma commercialization profile signals Compass is staffing its board for commercial launch of COMP360 psilocybin therapy.

At the APA Annual Meeting in San Francisco (May 16-20, 2026), Compass Pathways CEO George Goodwin framed COMP360 psilocybin-assisted therapy as neither mushrooms nor psychotherapy but a distinct technology-enabled therapeutic modality. The dispatch from Psychedelic Alpha (published June 2) captured an institutional inflection point: mainstream American psychiatry actively grappling with how to integrate psilocybin-assisted therapy. Goodwin's positioning validates Spirit Tech's sector thesis that technology platforms — not raw compounds — define the commercial opportunity. Builds on ART0182 (Week 22, COMP360 suicidal ideation study).